Algorae Pharmaceuticals (ASX: 1AI) has appointed industry executive Dr Sarah Siggins to its scientific advisory board.
Dr Siggins has more than 14 years of pharmaceutical experience, including senior roles at global companies Johnson & Johnson Innovative Medicine (Asia Pacific) and Bristol-Myers Squibb, where she led the development and execution of medical strategies across neuroscience, oncology, cardiopulmonary and immunology.
She holds a doctorate in biosciences from the University of Helsinki and has authored more than 15 peer-reviewed publications.
Dr Siggins joins the scientific advisory board following the initial readout this week of 24 artificial intelligence-generated drugs delivered by the AlgoraeOS drug discovery platform.
The targets are applicable to a range of oncology medical indications with significant unmet needs including breast and lung cancer, leukaemia and glioblastoma.
They have been reviewed for their commercial and intellectual property potential and will progress to preclinical studies at an Australian pharmaceutical drug laboratory.
Dr Siggins will provide strategic advice on potential commercial partnerships relating to AI-generated and other drug targets owned by Algorae.
Algorae chair David Hainsworth said Dr Siggins’ “unparalleled experience” in pharmaceutical innovation and strategic execution would be invaluable as Algorae advances its pipeline of drug candidates.
“Sarah brings with her a deep understanding of the Asia-Pacific regulatory and commercialisation environment and we believe she will be a key contributor to our scientific advisory board,” he said.
“We look forward to her contributions in guiding our company through its next phase of growth and innovation.”
Dr Siggins welcomed the opportunity to join Algorae.
“I look forward to working with the board and scientific team to enable Algorae to advance the development of new technologies and innovative therapies in diseases with high unmet needs,” she said.
“This is an exciting time to be involved in such programs with a dedicated team as they lead the way to improve patient outcomes and quality of life.”
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。